Hoth Therapeutics, Inc. (HOTH)

NASDAQ: HOTH · IEX Real-Time Price · USD
0.631
-0.085 (-11.86%)
At close: Jan 21, 2022 4:00 PM
0.630
0.000 (-0.079%)
After-hours:Jan 21, 2022 7:50 PM EST
Market Cap15.12M
Revenue (ttm)n/a
Net Income (ttm)-11.59M
Shares Out23.97M
EPS (ttm)-0.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume680,683
Open0.702
Previous Close0.715
Day's Range0.630 - 0.740
52-Week Range0.630 - 3.500
Beta0.99
AnalystsStrong Buy
Price Target3.88 (+515.4%)
Earnings Daten/a

About HOTH

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SA...

IndustryPharmaceuticals
IPO DateFeb 15, 2019
Employees3
Stock ExchangeNASDAQ
Ticker SymbolHOTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price forecast is 3.88.

Price Target
$3.88
(515.38% upside)
Analyst Consensus: Strong Buy

News

These Emerging Biotechs Could Beat Alzheimer's Disease

The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.

Other symbols:ABBVBIIBBMYJNJLGVNPFE
2 weeks ago - GuruFocus

HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today?

Investors in Hoth Therapeutics and HOTH stock have seen their investment go parabolic today on a key update for one of the company's drugs. The post HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketi...

2 weeks ago - InvestorPlace

Why Hoth Therapeutics Stock Is Soaring Today?

Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.  HT-ALZ is in development under t...

2 weeks ago - Benzinga

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Inform...

Other symbols:IMMXPSTV
2 weeks ago - PennyStocks

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced proof-of-concept data generated using an Alzheimer's disease...

2 weeks ago - PRNewsWire

Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to th...

1 month ago - PRNewsWire

Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleas...

1 month ago - PRNewsWire

EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zylö

Hoth Therapeutics Inc (NASDAQ: HOTH) has agreed to license its cannabinoid therapeutic, HT-005, for lupus patients back to Zylö Therapeutics. What Happened: In August 2019, Hoth Therapeutics and Zylö Th...

1 month ago - Benzinga

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is plea...

1 month ago - PRNewsWire

Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT

NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it has signed a Sponsored Research Agreement with Nort...

2 months ago - PRNewsWire

Hoth Therapeutics: Emerging Biotech With a Diversified Pipeline

The biopharmaceutical industry is a high-risk, high-reward industry where stocks soar and plummet with the approval or rejection of drugs. In addition, a strict regulatory framework must govern this sec...

2 months ago - GuruFocus

Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therape...

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical...

2 months ago - PRNewsWire

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

NEW YORK, Oct. 19, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc . (NASDAQ: HOTH) has extended its partnership agreement with  REPROCELL to assess the effect of the HT-003 therapeutic platform in inflamm...

3 months ago - PRNewsWire

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Der...

NEW YORK, NY  / PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ:  HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence coho...

3 months ago - Benzinga

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Der...

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to comm...

3 months ago - PRNewsWire

Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety...

4 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in hum...

4 months ago - PRNewsWire

Best Penny Stocks To Buy Now? 3 To Watch Amid SPRT Short Squeeze

Which penny stocks are investors watching amid the SPRT stock short squeeze? The post Best Penny Stocks To Buy Now?

Other symbols:NAOVRIDE
4 months ago - PennyStocks

Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Publishe...

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that i...

5 months ago - PRNewsWire

Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

Hoth Therapeutics Inc (NASDAQ: HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The study aims to determine the effects of HT-ALZ on behavioral and pathological mark...

5 months ago - Benzinga

Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's H...

5 months ago - PRNewsWire

Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model.  The model showed that HT-003 reduces toll-like rece...

6 months ago - Benzinga

Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment ...

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in...

6 months ago - PRNewsWire

Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the...

NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinica...

6 months ago - PRNewsWire

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic...

NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it has entered into a Sponsored Research Agreement with...

7 months ago - PRNewsWire